Plasma cell subtypes analyzed using artificial intelligence algorithm for predicting biochemical recurrence, immune escape potential, and immunotherapy response of prostate cancer.

Journal: Frontiers in immunology
Published Date:

Abstract

BACKGROUND: Plasma cells as an important component of immune microenvironment plays a crucial role in immune escape and are closely related to immune therapy response. However, its role for prostate cancer is rarely understood. In this study, we intend to investigate the value of a new plasma cell molecular subtype for predicting the biochemical recurrence, immune escape and immunotherapy response in prostate cancer.

Authors

  • Xiao Xie
    Department of Urology, The Third Affiliated Hospital of Southern Medical University, Guangzhou, China.
  • Chun-Xia Dou
    College of nursing, Jinan University, Guangzhou, China.
  • Ming-Rui Luo
    State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, China.
  • Ke Zhang
    Center for Radiation Oncology, Affiliated Hangzhou Cancer Hospital, Zhejiang University School of Medicine, Hangzhou 310001, China.
  • Yang Liu
    Department of Computer Science, Hong Kong Baptist University, Hong Kong, China.
  • Jia-Wei Zhou
    Department of Urology, The Third Affiliated Hospital of Southern Medical University, Guangzhou, China.
  • Zhi-Peng Huang
    Department of Urology, The Third Affiliated Hospital of Southern Medical University, Guangzhou, China.
  • Kang-Yi Xue
    Department of Urology, The Third Affiliated Hospital of Southern Medical University, Guangzhou, China.
  • Hao-Yu Liang
    Department of Urology, The Third Affiliated Hospital of Southern Medical University, Guangzhou, China.
  • Ao-Rong Ouyang
    Department of Urology, The Third Affiliated Hospital of Southern Medical University, Guangzhou, China.
  • Sheng-Xiao Ma
    Department of Urology, The Third Affiliated Hospital of Southern Medical University, Guangzhou, China.
  • Jian-Kun Yang
    Department of Urology, The Third Affiliated Hospital of Southern Medical University, Guangzhou, China.
  • Qi-Zhao Zhou
    Department of Urology, The Third Affiliated Hospital of Southern Medical University, Guangzhou, China.
  • Wen-Bing Guo
    Department of Urology, The Third Affiliated Hospital of Southern Medical University, Guangzhou, China.
  • Cun-Dong Liu
    Department of Urology, The Third Affiliated Hospital of Southern Medical University, Guangzhou, China.
  • Shan-Chao Zhao
    Department of Urology, The Third Affiliated Hospital of Southern Medical University, Guangzhou, China.
  • Ming-Kun Chen
    Department of Urology, The Third Affiliated Hospital of Southern Medical University, Guangzhou, China.